Name (Synonyms) | Correlation | |
---|---|---|
drug528 | Carrimycin Wiki | 1.00 |
drug2873 | lopinavir/ritonavir tablets or Arbidol or chloroquine phosphate Wiki | 1.00 |
drug2753 | basic treatment Wiki | 0.71 |
drug923 | Favipiravir Wiki | 0.24 |
Name (Synonyms) | Correlation | |
---|---|---|
D003141 | Communicable Diseases NIH | 0.09 |
D007239 | Infection NIH | 0.06 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
There is one clinical trial.
To address the need to intervene to prevent the spread of COVID-19 in long-term care homes, we propose a randomized clinical trial of chemoprophylaxis in long-term care homes experiencing COVID-19 outbreaks. LTCH units experiencing an outbreak of COVID-19 will be randomized to chemoprophylaxis with favipiravir or placebo in a 1:1 ratio. Chemoprophylaxis in this setting refers to the use of favipiravir for pre-exposure prophylaxis, post-exposure prophylaxis, pre-emptive therapy, or treatment for established COVID-19. This design mimics the approach to influenza outbreaks, which has proven efficacy for outbreak control. The primary outcome will be control of the outbreak, defined as no new microbiologically confirmed case of COVID-19 for 24 consecutive days up to day 40.
Description: Control of outbreak, defined as no new cases of COVID-19 in residents for 24 consecutive days up to day 40 after the start of prophylaxis
Measure: Control of Outbreak Time: Day 40Description: The proportion of residents of included LTCH units who die up to day 40, and up to day 60
Measure: Mortality (Residents) Time: Day 40, Day 60Description: The proportion of residents of included LTCH units who were uninfected at baseline and develop new symptomatic microbiologically confirmed COVID-19 up to day 40
Measure: COVID-19 Infection (Residents) Time: Day 40Description: The proportion of exposed staff uninfected at baseline in whom SARS-CoV-2 infection is identified up to day 14 and up to day 40
Measure: COVID-19 Infection (Staff) Time: Day 14, Day 40Description: The proportion of residents of included LTCH units hospitalized up to day 40
Measure: Hospitalization (Residents) Time: Day 40Description: The proportion of residents of included LTCH units who discontinue study medication due to adverse events
Measure: Medication Discontinuation (Residents) Time: Day 40Description: The proportion of LTCH staff of included LTCH units who discontinue study medication due to adverse events
Measure: Medication Discontinuation (Staff) Time: Day 40Description: The occurrence of new microbiologically confirmed COVID-19 infections in residents in other units of the LTCH up to day 40 (dichotomous, at LTCH level)
Measure: COVID-19 in new LTCH Units (a) Time: Day 40Description: The proportion of previously unaffected LTCH units of the remainder of the LTCH in which a case of COVID-19 is identified
Measure: COVID-19 in new LTCH Units (b) Time: Day 40Description: The proportion of residents in the remainder of the LTCH who develop COVID-19 infections up to day 40
Measure: COVID-19 in new LTCH Units (c) Time: Day 40